|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
on1319037529 |
| 003 |
OCoLC |
| 005 |
20241006213017.0 |
| 006 |
m o d |
| 007 |
cr un|---aucuu |
| 008 |
220519s2022 sz a o 000 0 eng d |
| 040 |
|
|
|a GW5XE
|b eng
|e rda
|e pn
|c GW5XE
|d YDX
|d EBLCP
|d OCLCF
|d UKAHL
|d OCLCQ
|d N$T
|d OCLCO
|d OCLCL
|d OCLCQ
|
| 019 |
|
|
|a 1317836590
|a 1318990083
|
| 020 |
|
|
|a 9783030963767
|q (electronic bk.)
|
| 020 |
|
|
|a 3030963764
|q (electronic bk.)
|
| 020 |
|
|
|z 9783030963750
|q (print)
|
| 020 |
|
|
|z 3030963756
|
| 024 |
7 |
|
|a 10.1007/978-3-030-96376-7
|2 doi
|
| 035 |
|
|
|a (OCoLC)1319037529
|z (OCoLC)1317836590
|z (OCoLC)1318990083
|
| 050 |
|
4 |
|a RC271.I45
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 072 |
|
7 |
|a MJCL
|2 thema
|
| 049 |
|
|
|a HCDD
|
| 245 |
0 |
0 |
|a Cancer immunotherapies :
|b solid tumors and hematologic malignancies /
|c Priya Hays, editors.
|
| 264 |
|
1 |
|a Cham, Switzerland :
|b Springer,
|c 2022.
|
| 300 |
|
|
|a 1 online resource (xvi, 315 pages) :
|b illustrations (some color).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Cancer treatment and research,
|x 2509-8497 ;
|v volume 183
|
| 505 |
0 |
|
|a Development of Cancer Immunotherapies -- Melanoma -- Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity -- Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer -- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma -- Lag3: From Bench to Bedside -- Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolution -- Immune-based therapeutic interventions for Acute Myeloid Leukemia.-Off-the-shelf chimeric antigen receptor immune cells from human pluripotent stem cells -- The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells -- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematological Malignancies.
|
| 520 |
|
|
|a This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (SpringerLink, viewed May 19, 2022).
|
| 650 |
|
0 |
|a Cancer
|x Immunotherapy.
|
| 650 |
|
7 |
|a Cancer
|x Immunotherapy
|2 fast
|
| 700 |
1 |
|
|a Hays, Priya,
|d 1968-
|e editor.
|1 https://id.oclc.org/worldcat/entity/E39PCjJbtDymwYWTG4hymdwQYK
|
| 776 |
0 |
8 |
|i Print version:
|z 3030963756
|z 9783030963750
|w (OCoLC)1292588598
|
| 830 |
|
0 |
|a Cancer treatment and research ;
|v v. 183.
|x 2509-8497
|
| 856 |
4 |
0 |
|u https://holycross.idm.oclc.org/login?auth=cas&url=https://link.springer.com/10.1007/978-3-030-96376-7
|y Click for online access
|
| 903 |
|
|
|a SPRING-MED2022
|
| 994 |
|
|
|a 92
|b HCD
|